185 related articles for article (PubMed ID: 24118702)
1. Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate.
Oraki Kohshour M; Mirzaie S; Zeinali M; Amin M; Said Hakhamaneshi M; Jalili A; Mosaveri N; Jamalan M
Chem Biol Drug Des; 2014 Mar; 83(3):259-65. PubMed ID: 24118702
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab.
Chen JL; Wang JY; Tsai YF; Lin YH; Tseng LM; Chang WC; King KL; Chen WS; Chiu JH; Shyr YM
Menopause; 2013 Jun; 20(6):646-54. PubMed ID: 23340260
[TBL] [Abstract][Full Text] [Related]
4. The importance of cellular internalization of antibody-targeted carbon nanotubes in the photothermal ablation of breast cancer cells.
Marches R; Mikoryak C; Wang RH; Pantano P; Draper RK; Vitetta ES
Nanotechnology; 2011 Mar; 22(9):095101. PubMed ID: 21258147
[TBL] [Abstract][Full Text] [Related]
5. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells.
Huang R; Sun Y; Gao Q; Wang Q; Sun B
Anticancer Drugs; 2015 Oct; 26(9):957-63. PubMed ID: 26186063
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
9. Photothermal effects of multi-walled carbon nanotubes on the viability of BT-474 cancer cells.
Chou HT; Wang TP; Lee CY; Tai NH; Chang HY
Mater Sci Eng C Mater Biol Appl; 2013 Mar; 33(2):989-95. PubMed ID: 25427516
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel.
Sun B; Feng SS
Nanomedicine (Lond); 2009 Jun; 4(4):431-45. PubMed ID: 19505246
[TBL] [Abstract][Full Text] [Related]
11. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin.
Yoong SL; Wong BS; Zhou QL; Chin CF; Li J; Venkatesan T; Ho HK; Yu V; Ang WH; Pastorin G
Biomaterials; 2014 Jan; 35(2):748-59. PubMed ID: 24140044
[TBL] [Abstract][Full Text] [Related]
13. Additive effects of trastuzumab and genistein on human breast cancer cells.
Lattrich C; Lubig J; Springwald A; Goerse R; Ortmann O; Treeck O
Anticancer Drugs; 2011 Mar; 22(3):253-61. PubMed ID: 21160418
[TBL] [Abstract][Full Text] [Related]
14. [Killing effect of Photofrin-Herceptin immunoconjugate on tumor cell lines in vitro].
Qian XY; Luo RC; Li LB; Liao WJ; Luo YL
Di Yi Jun Yi Da Xue Xue Bao; 2005 Aug; 25(8):975-8. PubMed ID: 16109553
[TBL] [Abstract][Full Text] [Related]
15. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells.
Gilabert-Oriol R; Thakur M; von Mallinckrodt B; Hug T; Wiesner B; Eichhorst J; Melzig MF; Fuchs H; Weng A
Mol Pharm; 2013 Nov; 10(11):4347-57. PubMed ID: 24050452
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction.
Akabani G; Carlin S; Welsh P; Zalutsky MR
Nucl Med Biol; 2006 Apr; 33(3):333-47. PubMed ID: 16631082
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
19. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin.
Datir SR; Das M; Singh RP; Jain S
Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830
[TBL] [Abstract][Full Text] [Related]
20. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.
Garcia AG; Nedev H; Bijian K; Su J; Alaoui-Jamali MA; Saragovi HU
Oncogene; 2013 May; 32(20):2527-33. PubMed ID: 22797066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
